Skip to main content
Erschienen in: Endocrine 2/2015

01.03.2015 | Original Article

Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients

verfasst von: Alice Albu, Serban Radian, Simona Fica, Carmen Gabriela Barbu

Erschienen in: Endocrine | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

The aim of the study was to determine whether Romanian polycystic ovary syndrome (PCOS) patients have an increased prevalence of metabolic syndrome (MetS) and to study the involvement of adiposity, insulin resistance and hyperandrogenism in the pathogenesis of MetS in PCOS. A total of 398 PCOS patients and 126 controls were evaluated between January 2006 and December 2012. MetS was defined by National Cholesterol Education Program, Adult Treatment Panel III criteria. Principal component analysis (PCA) was used to analyze the correlations among variables of interest by grouping them in few components, and principal component (PCs) scores were saved and used as independent variables in logistic regression. The prevalence of MetS was higher among patients with PCOS (20.4 %) than in controls (11.1 %, p < 0.05). In PCOS patients, PCA extracted three PCs from the analyzed variables. First PC aggregated variables related to adiposity and insulin resistance, with factor loadings showing strong relationship between these parameters. The second PC included markers of hyperandrogenemia and was best represented by free androgen index (FAI) which correlated strongly and exclusively with this PC. The third component was best represented by hirsutism. Logistic regression analysis revealed that in PCOS patients, the first and the second PCs were independently associated with MetS, whereas the third component was not. Romanian PCOS patients have an increased risk for MetS; adiposity, insulin resistance and hyperandrogenemia, but not hirsutism, are independent predictors of MetS presence. Our data also suggest that insulin resistance is only secondary to increased adiposity and FAI is a good marker of biochemical hyperandrogenism with little influences from the metabolic component.
Literatur
1.
Zurück zum Zitat I.F. Stein, M.L. Leventhal, Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181–191 (1935) I.F. Stein, M.L. Leventhal, Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181–191 (1935)
2.
Zurück zum Zitat P. Scicchitano, I. Dentamaro, R. Carbonara, G. Bulzis, A. Dachille, P. Caputo, R. Riccardi, M. Locorotondo, C. Mandurino, Ciccone MM, Cardiovascular risk in women with PCOS. Int. J. Endocrinol. Metab. 10(4), 611–618 (2012)CrossRefPubMedCentralPubMed P. Scicchitano, I. Dentamaro, R. Carbonara, G. Bulzis, A. Dachille, P. Caputo, R. Riccardi, M. Locorotondo, C. Mandurino, Ciccone MM, Cardiovascular risk in women with PCOS. Int. J. Endocrinol. Metab. 10(4), 611–618 (2012)CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16(4), 347–363 (2010)CrossRefPubMed L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16(4), 347–363 (2010)CrossRefPubMed
4.
Zurück zum Zitat J. Vrbikova, K. Vondra, D. Cibula, K. Dvoráková, S. Stanická, D. Srámková, G. Sindelka, M. Hill, B. Bendlová, J. Skrha, Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum. Reprod. 20(12), 3328–3332 (2005)CrossRefPubMed J. Vrbikova, K. Vondra, D. Cibula, K. Dvoráková, S. Stanická, D. Srámková, G. Sindelka, M. Hill, B. Bendlová, J. Skrha, Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum. Reprod. 20(12), 3328–3332 (2005)CrossRefPubMed
5.
Zurück zum Zitat E. Carmina, N. Napoli, R.A. Longo, G.B. Rini, R.A. Lobo, Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur. J. Endocrinol. 154(1), 141–145 (2006)CrossRefPubMed E. Carmina, N. Napoli, R.A. Longo, G.B. Rini, R.A. Lobo, Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur. J. Endocrinol. 154(1), 141–145 (2006)CrossRefPubMed
6.
Zurück zum Zitat C.J. Glueck, S. Dharashivkar, P. Wang, B. Zhu, P.S. Gartside, T. Tracy, L. Sieve, Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur. J. Obstet. Gynecol. Reprod. Biol. 122, 206–212 (2005)CrossRefPubMed C.J. Glueck, S. Dharashivkar, P. Wang, B. Zhu, P.S. Gartside, T. Tracy, L. Sieve, Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. Eur. J. Obstet. Gynecol. Reprod. Biol. 122, 206–212 (2005)CrossRefPubMed
7.
Zurück zum Zitat H.L. Ching, V. Burke, B.G. Stuckey, Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin. Endocrinol. Oxf. 66, 373–379 (2007)CrossRefPubMed H.L. Ching, V. Burke, B.G. Stuckey, Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin. Endocrinol. Oxf. 66, 373–379 (2007)CrossRefPubMed
8.
Zurück zum Zitat J.C. Lo, S.L. Feigenbaum, J. Yang, A.R. Pressman, J.V. Selby, A.S. Go, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 1357–1363 (2006)CrossRefPubMed J.C. Lo, S.L. Feigenbaum, J. Yang, A.R. Pressman, J.V. Selby, A.S. Go, Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 1357–1363 (2006)CrossRefPubMed
9.
Zurück zum Zitat N. Schweighofer, E. Lerchbaum, O. Trummer, V. Schwetz, S. Pilz, T.R. Pieber, B. Obermayer-Pietsch, Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome. Gene 504, 133–139 (2012)CrossRefPubMed N. Schweighofer, E. Lerchbaum, O. Trummer, V. Schwetz, S. Pilz, T.R. Pieber, B. Obermayer-Pietsch, Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome. Gene 504, 133–139 (2012)CrossRefPubMed
10.
Zurück zum Zitat E. Carmina, R.S. Legro, K. Stamets, J. Lowell, R.A. Lobo, Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18(11), 2289–2293 (2003)CrossRefPubMed E. Carmina, R.S. Legro, K. Stamets, J. Lowell, R.A. Lobo, Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum. Reprod. 18(11), 2289–2293 (2003)CrossRefPubMed
11.
Zurück zum Zitat S.F. Witchel, S.E. Recabarren, F. Gonzalez, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 42(3), 526–534 (2012). doi:10.1007/s12020-012-9701-4 CrossRefPubMedCentralPubMed S.F. Witchel, S.E. Recabarren, F. Gonzalez, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 42(3), 526–534 (2012). doi:10.​1007/​s12020-012-9701-4 CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat D.A. Ehrmann, D.R. Liljenquist, K. Kasza, R. Azziz, R.S. Legro, M.N. Ghazzi, PCOS/Troglitazone Study Group, Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 48–53 (2006)CrossRefPubMed D.A. Ehrmann, D.R. Liljenquist, K. Kasza, R. Azziz, R.S. Legro, M.N. Ghazzi, PCOS/Troglitazone Study Group, Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91, 48–53 (2006)CrossRefPubMed
13.
Zurück zum Zitat A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. Vanvoorhis, D.H. Jagasia, Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol. 106, 131–137 (2005)CrossRefPubMed A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. Vanvoorhis, D.H. Jagasia, Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet. Gynecol. 106, 131–137 (2005)CrossRefPubMed
14.
Zurück zum Zitat A.M. Corbould, M.J. Bawden, T.C. Lavranos, R.J. Rodgers, S.J. Judd, The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int. J. Obes. Relat. Metab. Disord. 26(2), 165–175 (2002)CrossRefPubMed A.M. Corbould, M.J. Bawden, T.C. Lavranos, R.J. Rodgers, S.J. Judd, The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int. J. Obes. Relat. Metab. Disord. 26(2), 165–175 (2002)CrossRefPubMed
15.
Zurück zum Zitat J.C. Lovejoy, G.A. Bray, M.O. Bourgeois, R. Macchiavelli, J.C. Rood, C. Greeson, C. Partington, Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—a clinical research center study. J. Clin. Endocrinol. Metab. 81(6), 2198–2203 (1996)PubMed J.C. Lovejoy, G.A. Bray, M.O. Bourgeois, R. Macchiavelli, J.C. Rood, C. Greeson, C. Partington, Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—a clinical research center study. J. Clin. Endocrinol. Metab. 81(6), 2198–2203 (1996)PubMed
16.
Zurück zum Zitat A. Gambineri, C. Pelusi, S. Genghini, A.M. Morselli-Labate, M. Cacciari, U. Pagotto, R. Pasquali, Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. 60(2), 241–249 (2004)CrossRef A. Gambineri, C. Pelusi, S. Genghini, A.M. Morselli-Labate, M. Cacciari, U. Pagotto, R. Pasquali, Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. 60(2), 241–249 (2004)CrossRef
17.
Zurück zum Zitat M. Allemand, Y. Asmann, K. Klaus, K. Nair, An model for PCOS related insulin resistance: the effects of testosterone on phosphorylation of intracellular insulin signaling proteins in rat skeletal muscle primary culture. Fertil. Steril. 84(Suppl 1), S30–S31 (2005)CrossRef M. Allemand, Y. Asmann, K. Klaus, K. Nair, An model for PCOS related insulin resistance: the effects of testosterone on phosphorylation of intracellular insulin signaling proteins in rat skeletal muscle primary culture. Fertil. Steril. 84(Suppl 1), S30–S31 (2005)CrossRef
18.
Zurück zum Zitat A. Corbould, Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192(3), 585–594 (2007)CrossRefPubMed A. Corbould, Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J. Endocrinol. 192(3), 585–594 (2007)CrossRefPubMed
19.
Zurück zum Zitat Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41–47 (2004)CrossRef
20.
Zurück zum Zitat H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman, Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 18(2), 146–170 (2012)CrossRefPubMed H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman, Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 18(2), 146–170 (2012)CrossRefPubMed
21.
Zurück zum Zitat Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Asoc. 285(19), 2486–2497 (2001)CrossRef Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Asoc. 285(19), 2486–2497 (2001)CrossRef
22.
Zurück zum Zitat D. Panidis, D. Macut, K. Tziomalos, E. Papadakis, K. Mikhailidis, E.A. Kandaraki, E.A. Tsourdi, T. Tantanasis, G. Mavromatidis, I. Katsikis, Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 78(4), 586–592 (2013)CrossRefPubMed D. Panidis, D. Macut, K. Tziomalos, E. Papadakis, K. Mikhailidis, E.A. Kandaraki, E.A. Tsourdi, T. Tantanasis, G. Mavromatidis, I. Katsikis, Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 78(4), 586–592 (2013)CrossRefPubMed
23.
Zurück zum Zitat J.J. Espinós-Gómez, J. Rodriguez-Espinosa, J. Ordóñez-Llanos, J. Calaf-Alsina, Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. Gynecol. Endocrinol. 28(4), 264–268 (2011)CrossRefPubMed J.J. Espinós-Gómez, J. Rodriguez-Espinosa, J. Ordóñez-Llanos, J. Calaf-Alsina, Metabolic syndrome in Mediterranean women with polycystic ovary syndrome: when and how to predict its onset. Gynecol. Endocrinol. 28(4), 264–268 (2011)CrossRefPubMed
24.
Zurück zum Zitat T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)CrossRefPubMed T. Apridonidze, P.A. Essah, M.J. Iuorno, J.E. Nestler, Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929–1935 (2005)CrossRefPubMed
25.
Zurück zum Zitat A.J. Cussons, G.F. Watts, V. Burke, J.E. Shaw, P.Z. Zimmet, B.G. Stuckey, Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum. Reprod. 23, 2352–2358 (2008)CrossRefPubMed A.J. Cussons, G.F. Watts, V. Burke, J.E. Shaw, P.Z. Zimmet, B.G. Stuckey, Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum. Reprod. 23, 2352–2358 (2008)CrossRefPubMed
26.
Zurück zum Zitat D. Berker, S. Koparal, S. Işik, L. Paşaoğlu, Y. Aydin, K. Erol, T. Delibaşi, S. Güler, Compatibility of different methods for the measurement of visceral fat in different body mass index strata. Diagn Interv Radiol. 16(2), 99–105 (2010)PubMed D. Berker, S. Koparal, S. Işik, L. Paşaoğlu, Y. Aydin, K. Erol, T. Delibaşi, S. Güler, Compatibility of different methods for the measurement of visceral fat in different body mass index strata. Diagn Interv Radiol. 16(2), 99–105 (2010)PubMed
27.
Zurück zum Zitat T.M. Barber, S.J. Golding, C. Alvey, J.A. Wass, F. Karpe, S. Franks, M.I. McCarthy, Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 93, 999–1004 (2008)CrossRefPubMed T.M. Barber, S.J. Golding, C. Alvey, J.A. Wass, F. Karpe, S. Franks, M.I. McCarthy, Global Adiposity Rather Than Abnormal Regional Fat Distribution Characterizes Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 93, 999–1004 (2008)CrossRefPubMed
28.
Zurück zum Zitat H.F. Escobar-Morreale, S. Samino, M. Insenser, M. Vinaixa, M. Luque-Ramírez, M.A. Lasunción, X. Correig, Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin. Chem. 58(6), 999–1009 (2009)CrossRef H.F. Escobar-Morreale, S. Samino, M. Insenser, M. Vinaixa, M. Luque-Ramírez, M.A. Lasunción, X. Correig, Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin. Chem. 58(6), 999–1009 (2009)CrossRef
29.
Zurück zum Zitat D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)CrossRefPubMed D. Dewailly, P. Pigny, B. Soudan, S. Catteau-Jonard, C. Decanter, E. Poncelet, A. Duhamel, Reconciling the Definitions of Polycystic Ovary Syndrome: The Ovarian Follicle Number and Serum Anti-Mullerian Hormone Concentrations Aggregate with the Markers of Hyperandrogenism. J. Clin. Endocrinol. Metab. 95, 4399–4405 (2010)CrossRefPubMed
30.
Zurück zum Zitat Alebić, M.S., Bulum, T., Stojanović, N., Duvnjak, L.: Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine. Feb 13. (2014) [Epub ahead of print] Alebić, M.S., Bulum, T., Stojanović, N., Duvnjak, L.: Definition of insulin resistance using the homeostasis model assessment (HOMA-IR) in IVF patients diagnosed with polycystic ovary syndrome (PCOS) according to the Rotterdam criteria. Endocrine. Feb 13. (2014) [Epub ahead of print]
31.
Zurück zum Zitat J.H. Fox, T. Licholai, G. Green, A. Dunaif, Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women. Fertil. Steril. 60(6), 994–1000 (1993)PubMed J.H. Fox, T. Licholai, G. Green, A. Dunaif, Differential effects of oral glucose-mediated versus intravenous hyperinsulinemia on circulating androgen levels in women. Fertil. Steril. 60(6), 994–1000 (1993)PubMed
32.
Zurück zum Zitat E.P. Wickham, K.G. Ewens, R.S. Legro, A. Dunaif, J.E. Nestler, J.F. Strauss 3rd, Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(4), 719–727 (2011)CrossRef E.P. Wickham, K.G. Ewens, R.S. Legro, A. Dunaif, J.E. Nestler, J.F. Strauss 3rd, Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 96(4), 719–727 (2011)CrossRef
33.
Zurück zum Zitat D. Glintborg, H. Mumm, P. Ravn, M. Andersen, Age associated differences in prevalence of individual Rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome. Horm. Metab. Res. 44(9), 694–698 (2012)CrossRefPubMed D. Glintborg, H. Mumm, P. Ravn, M. Andersen, Age associated differences in prevalence of individual Rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome. Horm. Metab. Res. 44(9), 694–698 (2012)CrossRefPubMed
34.
Zurück zum Zitat M.O. Goodarzi, N.A. Shah, H.J. Antoine, M. Pall, X. Guo, R. Azziz, Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J. Clin. Endocrinol. Metab. 91(10), 4085–4091 (2006)CrossRefPubMed M.O. Goodarzi, N.A. Shah, H.J. Antoine, M. Pall, X. Guo, R. Azziz, Variants in the 5alpha-reductase type 1 and type 2 genes are associated with polycystic ovary syndrome and the severity of hirsutism in affected women. J. Clin. Endocrinol. Metab. 91(10), 4085–4091 (2006)CrossRefPubMed
35.
Zurück zum Zitat W.Y. Chang, E.S. Knochenhauer, A.A. Bartolucci, R. Azziz, Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil. Steril. 83(6), 1717–1723 (2005)CrossRefPubMed W.Y. Chang, E.S. Knochenhauer, A.A. Bartolucci, R. Azziz, Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil. Steril. 83(6), 1717–1723 (2005)CrossRefPubMed
36.
Zurück zum Zitat J.S. Brand, I. van der Tweel, D.E. Grobbee, M.H. Emmelot-Vonk, Y.T. van der Schouw, Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol. 40, 189–207 (2011)CrossRefPubMed J.S. Brand, I. van der Tweel, D.E. Grobbee, M.H. Emmelot-Vonk, Y.T. van der Schouw, Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int. J. Epidemiol. 40, 189–207 (2011)CrossRefPubMed
37.
Zurück zum Zitat M.E. Zanolin, F. Tosi, G. Zoppini, R. Castello, G. Spiazzi, R. Dorizzi, M. Muggeo, P. Moghetti, Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 29, 372–378 (2006)CrossRefPubMed M.E. Zanolin, F. Tosi, G. Zoppini, R. Castello, G. Spiazzi, R. Dorizzi, M. Muggeo, P. Moghetti, Clustering of cardiovascular risk factors associated with the insulin resistance syndrome: assessment by principal component analysis in young hyperandrogenic women. Diabetes Care 29, 372–378 (2006)CrossRefPubMed
38.
Zurück zum Zitat P.M. Nilsson, G. Engström, B. Hedblad, The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects—a population-based study comparing three different definitions. Diabet. Med. 24, 464–472 (2007)CrossRefPubMed P.M. Nilsson, G. Engström, B. Hedblad, The metabolic syndrome and incidence of cardiovascular disease in non-diabetic subjects—a population-based study comparing three different definitions. Diabet. Med. 24, 464–472 (2007)CrossRefPubMed
39.
Zurück zum Zitat C. Lorenzo, M. Okoloise, K. Williams, M.P. Stern, S.M. Haffner, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26, 3153–3159 (2003)CrossRefPubMed C. Lorenzo, M. Okoloise, K. Williams, M.P. Stern, S.M. Haffner, The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 26, 3153–3159 (2003)CrossRefPubMed
40.
Zurück zum Zitat A.J. Hanley, A.J. Karter, K. Williams, A. Festa, R.B. D’Agostino Jr, L.E. Wagenknecht, S.M. Haffner, Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112, 3713–3721 (2005)CrossRefPubMed A.J. Hanley, A.J. Karter, K. Williams, A. Festa, R.B. D’Agostino Jr, L.E. Wagenknecht, S.M. Haffner, Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the insulin resistance atherosclerosis study. Circulation 112, 3713–3721 (2005)CrossRefPubMed
41.
Zurück zum Zitat R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRefPubMed R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456–488 (2009)CrossRefPubMed
42.
Zurück zum Zitat E. Lerchbaum, V. Schwetz, A. Giuliani, T.R. Pieber, B. Obermayer-Pietsch, Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil. Steril. 98, 1318–1325 (2012)CrossRefPubMed E. Lerchbaum, V. Schwetz, A. Giuliani, T.R. Pieber, B. Obermayer-Pietsch, Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome. Fertil. Steril. 98, 1318–1325 (2012)CrossRefPubMed
Metadaten
Titel
Biochemical hyperandrogenism is associated with metabolic syndrome independently of adiposity and insulin resistance in Romanian polycystic ovary syndrome patients
verfasst von
Alice Albu
Serban Radian
Simona Fica
Carmen Gabriela Barbu
Publikationsdatum
01.03.2015
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0340-9

Weitere Artikel der Ausgabe 2/2015

Endocrine 2/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.